Canaccord lowered the firm’s price target on Veracyte (VCYT) to $40 from $43 and keeps a Hold rating on the shares. The firm updated its model ahaead of Q1 results and they believe the shares could be attractive with continued momentum or additional material share price pullback. They are optimistic regarding the tools and diagnostics sector from the company-specific and macro perspectives.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCYT:
- Veracyte initiated with a Buy at Jefferies
- Veracyte: Leveraging TrueMRD and Decipher Bladder to Capture a $200M Minimal Residual Disease Opportunity
- Veracyte price target lowered to $45 from $50 at Guggenheim
- Veracyte Appoints Kevin Haas as Chief Technology Leader
- Veracyte names Kevin Haas as Chief Development and Technology Officer